4-tert-butyl-N-(4-chloro-2-(4-morpholino-1H-[1,2,3]triazolo[4,5-c]pyridine-1-yl)phenyl)benzenesulfonamide | 1094757-87-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-tert-butyl-N-(4-chloro-2-(4-morpholino-1H-[1,2,3]triazolo[4,5-c]pyridine-1-yl)phenyl)benzenesulfonamide
• 英文别名: 4-tert-butyl-N-(4-chloro-2-(4-morpholino-1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)phenyl)benzenesulfonamide；4-tert-butyl-N-[4-chloro-2-(4-morpholin-4-yltriazolo[4,5-c]pyridin-1-yl)phenyl]benzenesulfonamide
• CAS: 1094757-87-5
• 化学式: C₂₅H₂₇ClN₆O₃S
• 分子量: 527.047
• InChiKey: RVWKTSXAZSTVQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL) HETARYL ARYLSULFONAMIDES
  申请人：Charvat Trevor T.

  公开号：US20090005410A1

  公开（公告）日：2009-01-01

  Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

  提供了作为CCR9受体强效拮抗剂的化合物。动物实验表明，这些化合物对于治疗炎症非常有效，而炎症是CCR9的典型疾病特征。这些化合物通常是芳基磺酰胺衍生物，可用于制药组合物、治疗CCR9介导疾病的方法，以及作为鉴定CCR9拮抗剂的检测中的对照物。
• N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES
  申请人：Charvat Trevor T.

  公开号：US20120245138A1

  公开（公告）日：2012-09-27

  Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

  提供了作为CCR9受体的有效拮抗剂的化合物。动物实验表明这些化合物对于治疗CCR9标志性疾病炎症是有用的。这些化合物通常是芳基磺酰胺衍生物，可用于制药组合物、治疗CCR9介导的疾病的方法，以及作为鉴定CCR9拮抗剂的试验控制。
• N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES
  申请人：Charvat Trevor T.

  公开号：US20100331302A1

  公开（公告）日：2010-12-30

  Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

  提供了一些化合物，它们作为CCR9受体的有效拮抗剂。动物实验表明，这些化合物对于治疗CCR9标志性疾病炎症非常有用。这些化合物通常是芳基磺酰胺衍生物，并且在制药组合物、治疗CCR9介导疾病的方法以及用于识别CCR9拮抗剂的测定中作为对照物质非常有用。
• Abuse-proofed dosage form
  申请人：Bartholomaus Johannes

  公开号：US20050152843A1

  公开（公告）日：2005-07-14

  The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.

  本发明涉及一种防止非肠道滥用的固体给药形式，除了一种或多种具有非肠道滥用潜能的活性物质外，还含有至少一种增粘剂。当加入必要的最低量的水性液体时，该药剂在从给药形式中提取的基础上形成一种优选的可注射凝胶，该凝胶在加入另一种数量的水性液体时在视觉上仍然是独特的。
• N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES
  申请人：ChemoCentryx, Inc.

  公开号：EP2170823B1

  公开（公告）日：2014-08-06